A Randomised, Double-Blind, Parallel-Group, Multicentre, Phase III Study to Evaluate the Effect of Ticagrelor versus Placebo in Reducing the Rate of Vaso-Occlusive Crises in Paediatric Patients with Sickle Cell Disease (HESTIA3)

drug protocol number
D5136C00009
drug sponsor
Astrazeneca
drug study
Ticagrelor
drug trial site
King Fahad Medical City (Riyadh), King Khalid University Hospital (Riyadh)
drug status
Ongoing
drug phase